Pfizer has released the full data from its phase 3 trial of an mRNA flu vaccine candidate, with the potential new shot demonstrating 34.5% greater efficacy compared to a control vaccine. | Pfizer has ...

Pfizer on Thursday closed its up to $10 billion acquisition of Metsera after winning shareholder approval, gaining a foothold ...

Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major ...

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Shares of Metsera fell over 15% in premarket trading on Monday, after the weight-loss drug developer accepted a sweetened ...

Now, it’s worth noting Stock Advisor’s total average return is 1,035% — a market-crushing outperformance compared to 191 % ...

After [losing out to Pfizer]( ...

Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

The approval paves the way for Pfizer to diversify beyond its shrinking ‌COVID-19 portfolio, navigate looming patent ...

Pfizer and Novo Nordisk are locked in a bidding war for biotech firm Metsera as the pharmaceutical giants seek to augment their pipeline in the booming weight-loss drug market. Metsera is a New ...

Pfizer said on Thursday it completed an acquisition worth up to $10 billion of biotech firm Metsera after winning shareholder ...